Healthcare & Life Sciences Insights

The EU regulation designed to facilitate secondary use of clinical data for research brings benefits for health research, but also poses challenges for companies.

In a 9-0 decision, the Court held that FDA has broad discretion to interpret the standard for marketing authorizations of new tobacco products under the Tobacco Control Act.

Firm’s shareholder activism defense and public company representation teams represented the clinical-stage biopharmaceutical company in agreement resulting in new independent board director and withdrawal of stockholder-nominated director candidates.

Multidisciplinary team represents the financing sources in the healthcare investment firm’s take-private acquisition of the dental and animal health distributor.